[
  {
    "id": "table_1_interpretation_criteria_for_the_quantiferon_tb_gold_plus_test",
    "subChapterId": 2,
    "subChapterText": "Interpretation Criteria for the QuantiFERON-TB Gold Plus Test (QFT-Plus)"
  },
  {
    "id": "table_2_interpretation_criteria_for_the_t_spot_tb_test",
    "subChapterId": 2,
    "subChapterText": "Interpretation Criteria for the T-SPOT.TB Test (TSpot)"
  },
  {
    "id": "table_3_high_prevalence_and_high_risk_groups",
    "subChapterId": 2,
    "subChapterText": "High Prevalence and High-Risk Groups"
  },
  {
    "id": "table_4_recommendations_for_regimens_to_treat_latent_tuberculosis_infection",
    "subChapterId": 2,
    "subChapterText": "Recommendations for regimens to treat latent tuberculosis infection"
  },
  {
    "id": "table_5_dosages_for_recommended_lbti_treatment_regimens",
    "subChapterId": 2,
    "subChapterText": "Dosages for recommended LBTI treatment regimens "
  },
  {
    "id": "table_6_ltbi_treatment_drug_adverse_reactions",
    "subChapterId": 2,
    "subChapterText": "LTBI Treatment Drug Adverse Reactions"
  }
]